Barclays Increases Pfizer Price Target to $34.00 (PFE)
Equities research analysts at Barclays boosted their target price on shares of Pfizer (NYSE:PFE) from $32.00 to $34.00 in a research note issued to investors on Wednesday. Barclays’ target price indicates a potential upside of 13.03% from the stock’s previous close.
Pfizer (NYSE:PFE) opened at 30.08 on Wednesday. Pfizer has a 52 week low of $27.33 and a 52 week high of $32.96. The stock’s 50-day moving average is $29.52 and its 200-day moving average is $30.69. The company has a market cap of $191.9 billion and a P/E ratio of 9.21.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.56 by $0.01. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the prior year, the company posted $0.54 earnings per share. The company’s quarterly revenue was down 8.5% on a year-over-year basis. Analysts expect that Pfizer will post $2.24 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, September 3rd. Shareholders of record on Friday, August 1st will be paid a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 3.46%. The ex-dividend date is Wednesday, July 30th.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Pfizer in a research note on Wednesday, May 28th. They set an “overweight” rating and a $35.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, May 27th. They now have a $31.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Pfizer in a research note on Tuesday, May 27th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the stock. Pfizer has a consensus rating of “Buy” and a consensus price target of $33.11.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.